Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant.

Cell and gene therapy leaders say the agency’s decision to remove the Risk Evaluation and Mitigation Strategies that had been ...

Market Growth Driven by Increasing Drug Approvals, Advanced Technologies, Rising Chronic Disease Incidence, and Expanding Therapeutic Applica ...

While CEO-designate Vas Narasimhan kept tightlipped on this point in the press conference, an answer came a few hours later, with a deal with groundbreaking gene therapy company Spark Therapeutics ...

Research Funding: Janssen, Novartis, Kite/Gilead, Bristol Myers Squibb, AstraZeneca, MorphoSys/Incyte, ADC Therapeutics, Genentech/Roche, Allogene Therapeutics No other potential conflicts of interest ...

Novartis’ Vas Narasimhan I spoke to Novartis’ head of drug development Vas Narasimhan in depth about the company’s CAR-T programme a few weeks ago, ahead of Kite’s latest announcement.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for rare diseases.

STOCKHOLM, SWEDEN June 27, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics carries out a fully secured rights issue of units of ...

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is among the best small company stocks to invest in. Stifel reaffirmed a Buy rating on Dianthus Therapeutics, Inc.

FREEHOLD, N.J. - Channel Therapeutics Corporation (NYSE American:CHRO), currently trading at $1.17 with a market capitalization of $7.72 million, announced a 10-for-1 reverse stock split of its ...

Rein Therapeutics has paused patient enrollment and dosing in a mid-stage trial of its lung disease drug in the U.S. after the Food and Drug Administration placed a clinical hold, the drug ...